Zydus Lifesciences reported a significant year-on-year decline of thirty-six percent in net profit for the first quarter, despite a robust twenty-two percent increase in operational revenue, reaching eight thousand seventeen crore rupees. The company experienced profitability challenges with an EBITDA reduction of seven point six percent compared to the previous year. Following the announcement, their stock price saw an uptick. Zydus is a prominent player in the global pharmaceutical landscape.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.